New Immunotherapy for Multiple Myeloma
The FDA granted accelerated approval to a targeted immunotherapy for patients with relapsed or refractory multiple myeloma. The U.S....
Progress Against Cancer
The FDA granted accelerated approval to a targeted immunotherapy for patients with relapsed or refractory multiple myeloma. The U.S....
The FDA approved the combination of two checkpoint inhibitors for certain patients with hepatocellular carcinoma. The U.S. Food and...
The FDA granted accelerated approval to a new targeted therapy for certain patients with advanced or metastatic cholangiocarcinoma. The...
The FDA granted accelerated approval to selpercatinib to treat solid tumors harboring RET gene fusions. The U.S. Food and...
The FDA granted full approval to selpercatinib for the treatment of patients with advanced lung cancer. The U.S. Food...
An inhibitor of the growth-stimulating FGFR1 protein was approved for patients with a rare type of blood cancer. The...
The FDA granted accelerated approval to the first HER2-targeted therapy for the treatment of non-small cell lung cancer with...
The FDA approved the kinase inhibitor capmatinib for lung cancers harboring a certain mutation in the protein MET. The...
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food...
The FDA approved darolutamide for the treatment of metastatic prostate cancer that is sensitive to hormone-blocking treatment. The U.S....